---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-214241"
form_type: "8-K"
ticker: "NUVB"
cik: "0001811063"
company_name: "Nuvation Bio Inc."
filed_at: "2024-09-05T23:59:59+00:00"
generated_at: "2026-05-31T06:17:35.328243+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Nuvation Bio shareholders approve 85M share conversion; CEO Hung named Board Chair

## Summary
- Shareholders approved conversion of Series A Preferred into up to 85,120,200 Class A shares; conversion completed Sept 4, resulting in 333.8M Class A shares outstanding.
- CEO David Hung appointed Chair of the Board; Robert Bazemore appointed Lead Independent Director.
- Committee chairs set: Falberg (Audit), Vernon (Compensation), Bazemore (Nominating/Governance).
- All five proposals passed: directors elected, KPMG ratified, executive compensation approved, conversion approved, adjournment approved.

## SEC filing metadata
- accession: 0001193125-24-214241
- form_type: 8-K
- ticker: NUVB
- cik: 0001811063
- company_name: Nuvation Bio Inc.
- filed_at: 2024-09-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.07, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1811063/000119312524214241/0001193125-24-214241-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1811063/000119312524214241/d888247d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-214241
- JSON: https://secwatch.observer/filing/0001193125-24-214241.json
- Plain text: https://secwatch.observer/filing/0001193125-24-214241.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.